)
The only ultrasensitive ctDNA assay
designed specifically for monitoring
Molecular Response & MRD
Measuring Molecular Response requires an assay that is cost effective over many time points, highly sensitive and specific, fast, quantitive and efficient with sample volume.
)
)
Unlimited
Unlimited
Unlimited time points
Fixed pricing for an unlimited number of timepoints per patient over the course of a study. The Tracer assay works with blood and urine samples.
)
Accurate
Accurate
Ultrasensitive assay
Per volume sensitivity and specificity best in the industry. Effective at lower blood volumes than conventional NGS-based ctDNA assays.
)
Fast
Fast
Rapid Turnaround
Leverage existing biomarker data for initial tumor-informed assay design and validation. Sub 7-day turnaround for subsequent samples.
PERSONALIZEDdPCR
)
The first tumor-informed ctDNA assay based on the digital PCR platform: industry leading sensitivity, specificity, and speed for unlimited timepoints.
Dose Escalation
& Optimization
Endpoint
Analysis
Surveillance
Tracer is the only ultrasensitive ctDNA assay for Molecular Response surveillance. Combining tumor-informed personalization with dPCR allows Tracer to offer cost-effective assays for an unlimited number of timepoints on a study. The Tracer assay is available for blood and urine.
)
)
CEO & FOUNDER
Mark Kaganovich
Prior to co-founding Tracer Biotechnologies Mark was the CEO and co-founder of SolveBio (acquired by Precision Medicine Group). Mark received his PhD in Genetics from Stanford University and AB in Biochemistry and Computer Science from Harvard University.
CSO & FOUNDER
Gopal
Ramachandran
Gopal is the co-founder and CSO of Tracer Biotechnologies. Previously he served as CTO of Wellframe (acquired by Blackstone). Gopal completed his postdoctoral work at the Broad Institute and received his PhD in Mathematics from MIT and MD from Harvard Medical School.
